Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dong-Lin Wang

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
BMC Veterinary Research|January 9, 2026
Analysis and identification of circRNA-regulated ceRNA networks associated with the virulence differences between PRV FA and FB strainsQiu-Yong Chen, Wen-Juan Zhao, Dong-Lin Wang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 13, 2006
[Docetaxel in the treatment of advanced breast cancer ]Zi-Ping Wang, Yan Sun, Xiang-Ru Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|November 26, 2008
[A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy]Zi-ping Wang, Yan Sun, Xiang-ru Zhang, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
BMC Veterinary Research|January 9, 2026
Analysis and identification of circRNA-regulated ceRNA networks associated with the virulence differences between PRV FA and FB strainsQiu-Yong Chen, Wen-Juan Zhao, Dong-Lin Wang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 13, 2006
[Docetaxel in the treatment of advanced breast cancer ]Zi-Ping Wang, Yan Sun, Xiang-Ru Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|November 26, 2008
[A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy]Zi-ping Wang, Yan Sun, Xiang-ru Zhang, et al.
Pageof 4